Analysts expect Thermo Fisher Scientific Inc. (NYSE:TMO) to post sales of $6.02 billion Six analysts have issued estimates for Thermo Fisher Scientific’s earnings. The lowest sales estimate is $5.97 billion and the highest is $6.06 billion. Thermo Fisher Scientific posted sales of $5.85 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 2.9%. The firm results before the market opens on Wednesday, April 24th.
According to Zacks, analysts expect that Thermo Fisher Scientific will report full year sales of $25.23 billion for the current year, with estimates ranging from $25.10 billion to $25.34 billion. For the next financial year, analysts expect that the company will post sales of $26.60 billion, with estimates ranging from $26.22 billion to $27.07 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow Thermo Fisher Scientific.
Get Thermo Fisher Scientific alerts: Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 30th. The medical research company reported $3.25 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.19 by $0.06. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.26 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 12.06%. Thermo Fisher Scientific’s revenue was up 7.6% on a year-over-year basis. During the same quarter last year, the company earned $2.79 EPS.
Several equities analysts have issued reports on the company. UBS Group lifted their price objective on Thermo Fisher Scientific to $305.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research report on Thursday, December 13th. BTIG Research lifted their price objective on Thermo Fisher Scientific to $290.00 and gave the company a “buy” rating in a research report on Thursday, January 31st. Barclays lifted their price objective on Thermo Fisher Scientific from $295.00 to $300.00 and gave the company Finally, Needham & Company LLC assumed coverage on Thermo Fisher Scientific in a research report on Wednesday, January 2nd. They issued a “strong-buy” rating and a $271.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $284.09.
Shares of Thermo Fisher Scientific stock traded up $1.44 during midday trading on Friday, hitting $276.49. 839,764 shares of the company were exchanged, compared to its average volume of 1,635,811. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.73 and a quick ratio of 1.24. The company has a market capitalization of $109.74 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 1.82 and a beta of 1.13. Thermo Fisher Scientific has a 52 week low of $202.83 and a 52 week high of $278.86.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 16th. Stockholders of record on Friday, March 15th will be given a dividend of $0.19 per share. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. Thermo Fisher Scientific’s payout ratio is presently 6.83%.
In other news, SVP Gregory J. Herrema sold 19,808 shares of the business’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $253.29, for a total transaction of $5,017,168.32. Following the completion of the sale, the senior vice president now owns 25,688 shares in the company, valued at $6,506,513.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink . Also, insider Gregory J. Herrema sold 3,299 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $263.05, for a total value of $867,801.95. The disclosure for this sale can be found here . In the last 90 days, insiders have sold 36,927 shares of company stock valued at $9,388,124. 0.49% of the stock is currently owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in TMO. Oregon Public Employees Retirement Fund raised its position in shares of Thermo Fisher Scientific by 44,296.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 19,565,960 shares of the medical research company’s stock worth $87,000 after acquiring an additional 19,521,889 shares during the last quarter. Norges Bank bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $946,280,000. Capital International Investors bought a new stake in shares of Thermo Fisher Scientific during the third quarter worth $868,413,000. Capital World Investors raised its position in shares of Thermo Fisher Scientific by 19.2% during the third quarter. Capital World Investors now owns 15,412,242 shares of the medical research company’s stock worth $3,761,820,000 after acquiring an additional 2,482,783 shares during the last quarter. Finally, FMR LLC raised its position in shares of Thermo Fisher Scientific by 33.4% during the fourth quarter. FMR LLC now owns 8,671,713 shares of the medical research company’s stock worth $1,940,642,000 after acquiring an additional 2,172,574 shares during the last quarter. Institutional investors own 88.66% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Story: Quiet Period Expirations
Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Thermo Fisher Scientific
